Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

rent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue $112 $84 $715 $187

Operating expenses:

Research and development 13,449 15,754 54,780 56,995

General and administrative 6,364 5,974 20,458 16,634

Total operating expenses 19,813 21,728 75,2
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
(Date:5/17/2013)... IAC Industries wants to share with you ... needing to set up and furnish a research lab knowing ... within a year’s time. How does a company make choices ... temporary? What is efficient and cost-effective? , The solution ... Industries. The planners at DisperSol determined that the concept of ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
Breaking Biology Technology:New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... Janssen Biotech, Inc. announced today that the ... Complete Response letter for its supplemental Biologics License ... in September 2010, seeks to expand the SIMPONI® ... structural damage, inducing major clinical response (MCR) and ...
... Calif., July 22, 2011 NeurogesX, Inc. (Nasdaq: ... novel pain management therapies, today announced that on July ... in connection with a private placement to a group ... conditions, is expected to receive approximately $20 million in ...
... (previously known as the Beijing Genomics Institute), the largest ... Zoology, Chinese Academy of Sciences, together published the whole ... ) in Genome Biology on July 6th, ... for evolutionary and biomedical research. Rhesus macaque, also ...
Cached Biology Technology:FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 2FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 3FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 4FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 5FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 6NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4Whole sequence variation map reveals insight into evolutionary studies of rhesus macaque 2
(Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
(Date:5/18/2013)... 2013) Research presented today at Digestive Disease Week ... findings about the impact of coffee on autoimmune disease ... coffee consumption recently has been associated with reduced risk ... few more cups of java each month also correlate ... Researchers at the Mayo Clinic, Rochester, MN, linked coffee ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... Ramat Rahel, located on a hilltop above modern-day Jerusalem. The ... kingdom of Biblical Judah, digs have also revealed a luxurious ... irrigation system, they could only imagine what the original garden ... Using a unique technique for separating fossilized pollen ...
... Brown University scientists have created the first three-dimensional ... analyze the effectiveness of therapeutics to combat brain tumors. ... information than Petri dish tissue cultures. The researchers ... of blood vessels that surrounds it. In a series ...
... Desert there is an ,oasis, of microorganisms. Researchers from the ... North in Chile have found it in hypersaline substrates thanks ... be used in environments similar to subsoil on Mars. ... A Spanish-Chilean team of scientists have found bacteria and archaea ...
Cached Biology News:Fossilized pollen unlocks secrets of ancient royal garden 2Fossilized pollen unlocks secrets of ancient royal garden 3Researchers make living model of brain tumor 2Microbial oasis discovered beneath the Atacama Desert 2
Cell Culture Flask, nontreated polystyrene...
... Corning CellBIND surface is produced by ... a more hydrophilic surface giving more ... growth and yields. CellBIND enhances cell ... including reduced serum or serum-free medium. ...
... array system, 100-240 V, uses xMAP technology ... 100 proteins and peptides in one microplate ... up to 100 color-coded bead sets, each ... unique reactant (enzyme substrates, receptors, antigens, or ...
... 100-240 V, is an optional module for ... delivery of up to 20 L of ... The HTF system automatically draws sheath fluid ... constantly maintain a reservoir of pressurized sheath ...
Biology Products: